Cost Effectiveness of a Potential Vaccine for Human papillomavirus by Sanders, Gillian D. & Taira, Al V.
Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 37
RESEARCH
Cost Effectiveness of a Potential 
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Human papillomavirus (HPV) infection, usually a sexually
transmitted disease, is a risk factor for cervical cancer. Given
the substantial disease and death associated with HPV and
cervical cancer, development of a prophylactic HPV vaccine is
a public health priority. We evaluated the cost-effectiveness of
vaccinating adolescent girls for high-risk HPV infections rela-
tive to current practice. A vaccine with a 75% probability of
immunity against high-risk HPV infection resulted in a life-
expectancy gain of 2.8 days or 4.0 quality-adjusted life days at
a cost of $246 relative to current practice (incremental cost
effectiveness of $22,755/quality-adjusted life year [QALY]). If all
12-year-old girls currently living in the United States were vac-
cinated, >1,300 deaths from cervical cancer would be averted
during their lifetimes. Vaccination of girls against high-risk HPV
is relatively cost effective even when vaccine efficacy is low. If
the vaccine efficacy rate is 35%, the cost effectiveness
increases to $52,398/QALY. Although gains in life expectancy
may be modest at the individual level, population benefits are
substantial.
ervical cancer is one of the most common malignancies
in women: this year in the United States, approximately
13,000 new cases will be diagnosed, and >4,000 women will
die of the disease. Fortunately, cervical cancer is highly pre-
ventable with regular Papanicolaou (Pap) testing. Between
1973 and 1995, the Surveillance, Epidemiology, and End
Results (SEER) Program (sponsored by the National Cancer
Institute) documented a 43% decrease in incidence and a 46%
decrease in death from cervical cancer. Such reductions, how-
ever, have not been observed in locations or countries where
cytologic testing is not widely available. Epidemiologic
research strongly implicates Human papillomavirus (HPV) as
the major risk factor for cervical cancer. Therefore, methods of
prevention, diagnosis, and treatment of HPV infection have
been pinpointed as a means of reducing the incidence of cervi-
cal cancer.
HPV comprises >100 different types of viruses; approxi-
mately 40 of these are transmitted sexually. Although most
HPV infections proceed and resolve without symptoms, some
types of HPV (such as 6 and 11) may cause genital warts,
whereas other types (such as 16 and 18) are associated with
certain types of cancer. HPV infections are recognized as the
major cause of cervical cancer: >90% of women who have cer-
vical cancer also have been infected with HPV (1–7). HPV
types that are correlated with the development of cancer are
referred to as high-risk. Although no medical means currently
exist to eliminate HPV infection, precancerous lesions and
warts caused by these viruses can be treated.
Given the substantial disease and death associated with
HPV and cervical cancer, research to develop a prophylactic
HPV vaccine is ongoing (8). Vaccines for HPV-16 and HPV-
18 are currently being studied in clinical trials; the Phase I trial
results are encouraging (9,10). The cost effectiveness of such
vaccines, however, has not been studied sufficiently. There-
fore, we evaluated the effectiveness and cost effectiveness of a
prophylactic vaccine. 
Data and Methods
We used a decision model to estimate the length of life and
expenditures for vaccination of adolescent girls for high-risk
HPV types (Figure 1). We adhered to the recommendations of
the Panel on Cost Effectiveness in Health and Medicine (11)
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Figure 1. Schematic representation of the decision model. In panel A,
the square node at the left represents the vaccination decision. The
woman’s health thereafter is simulated by a Markov model. Each
month, women are at risk of developing Human papillomavirus (HPV)
infection, SIL (squamous intraepithelial lesions), or cervical cancer.
Women who contract HPV may be infected by a low- or high-risk type.
Panel B demonstrates cervical-cancer diagnosis, treatment, and natu-
ral history. Throughout a woman’s lifetime, her HPV, SIL, or cervical
cancer status can be discovered either through development of symp-
toms or through routine Pap tests. Panel C shows that women who
undergo a Pap test may test negative or positive for SIL.RESEARCH
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for conducting and reporting a reference-case analysis. We
expressed our results in terms of costs, life-years, quality-
adjusted life-years (QALYs), and incremental cost-effective-
ness (ICE) ratios. We performed one-way sensitivity analyses
on all model variables, as well as multi-way sensitivity analy-
ses on selected variables.
Patient Population
The target population for this analysis was all adolescent
girls in the United States. Our base-case analysis considered a
hypothetical cohort of 12-year-old girls. A recent study by the
Centers for Disease Control and Prevention (CDC), indicated
that although 3% of girls have had sexual intercourse before
reaching age 13, 18.6% are sexually active by age 15, and
59.2% by age 18 (12). We therefore believed that vaccinating
12-year-old girls would capture most girls before they are sex-
ually active and are at risk for HPV infection. We examined
the optimal vaccination age in sensitivity analyses.
Our analysis assumes a universal vaccination strategy for
adolescent girls. Although risk factors for HPV infection are
identifiable, we chose to evaluate a universal vaccination pro-
gram for several reasons. Previous vaccination programs aimed
to reduce incidence of Hepatitis B virus (HBV) infection have
tried to target the risk groups that account for most cases (13).
These high-risk groups, however, are difficult to vaccinate for a
variety of reasons, including inaccessibility, noncompliance,
and the inability to identify people at risk. Also, because >30%
of HBV-infected persons show no identifiable risk factor for
infection (13,14), they would not be included in such a targeted
immunization strategy. Similarly for HPV infection, the broad
range of risk factors and the difficulty identifying these behav-
iors inhibit targeting such risk groups. We evaluated the cost-
effectiveness of targeting high-risk girls (assuming a reduced
compliance) in sensitivity analyses.
Decision Model
We used Decision Maker software (Pratt Medical Group,
Boston, MA, v2002.07.2) to develop a Markov model that fol-
lowed the girls over their lifetimes. For each strategy, our
model included probabilities of occurrence and progression of
HPV, of squamous intraepithelial lesions (SIL), and of cervical
cancer, as well as the probability of death, costs, and quality of
life associated with the various health states. Whenever possi-
ble, we based our probability estimates (Appendix) on large,
high-quality studies reported in the literature.
Our model (Figure 1A) tracks a cohort of girls who are
either vaccinated against specific HPV types or who receive
the current standard of care. Based on hepatitis B vaccination
completion rates among U.S. adolescents, we assumed that
70% of the targeted girls would be vaccinated successfully
(Appendix). We assumed that girls who were not vaccinated
would receive the current standard of care.
Every month, each girl is at risk of developing high- or
low-risk HPV, SIL, or cervical cancer. Over time, an infected
woman’s HPV infection can regress, persist, or progress to
either low- or high-grade SIL. SIL can also exist independent
of an HPV infection. High-grade SIL can progress to cervical
cancer. The diagnosis, treatment, and natural history of cervi-
cal cancer are modeled in Figure 1B. 
We assumed that the current standard of care included rou-
tine Pap tests for compliant patients every 2 years starting at
age 16. Throughout a woman’s lifetime, her HPV, SIL, or cer-
vical cancer status can be discovered and treated either
because symptoms have developed or through routine Pap
tests (Figure 1C). We assumed that 10% of woman diagnosed
with low-grade SIL would undergo cryotherapy and that all
would receive a 6-week reexamination, and Pap tests at 3, 6,
12, and 18 months after cryotherapy. Treatment of high-grade
SIL was assumed to include loop electrosurgical excision pro-
cedure (LEEP), and subsequent reexamination and Pap tests
(15,16).
A woman may also choose to have a benign hysterectomy
reducing her risk of cervical cancer. In addition to being at risk
for death because of cervical cancer, all women are at risk for
age-specific death unrelated to HPV or cervical cancer.
Data and Base-Case Assumptions
HPV Infection
Incidence of HPV infection was based on Myers’ mathe-
matical model of HPV infection (Appendix) (17). In our base-
case analysis, annual incidence began at age 15 (10%), peaked
at age 19 (18%), and dropped off quickly after age 29 (1%).
We assumed that no prevalent HPV infections existed in the
initial cohort of 12-year-old girls but varied this assumption in
sensitivity analyses. Given HPV infection, regression rates
were highest for women <25 years (46%/yr) and lowest for
women >30 years (7%/yr), reflecting a preponderance of more
persistent infections in the older age group (Appendix).
Low- Versus High-Risk HPV
Because of a lack of significant HPV genotype cross-
immunity, any vaccine developed probably will be effective
against a limited number of HPV types (18,19). HPV types 16,
18, 45, and 31 together are the most commonly associated with
cervical cancer, with evidence of these four types apparent in
>75% of women who have cervical cancer (20). In our model,
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
were considered high risk; all other HPV types were catego-
rized as low risk (20–22). Based upon this classification in the
general population, 59% of HPV infections are caused by
high-risk types (Appendix). 
Low- and High-Risk Rates of HPV Progression
To evaluate potential vaccination strategies, we modeled
different disease-progression rates in women infected with
low- and high-risk HPV. By combining data on overall pro-
gression rates of HPV infection to cancer, with prevalence data
on women infected with low- and high-risk HPV who had
low- or high-grade SIL or cervical cancer, we estimated sepa-Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 39
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rate progression rates for low- and high-risk HPV infections.
Data from seven articles were considered of high enough qual-
ity to be included in our analysis (1–7).
High-risk HPV infections were significantly more com-
mon in women who had cervical cancer than in women who
had precursor lesions. Based on the results of seven studies
(N=1609), high-risk HPV infection was detected in 56% of
women who had low-grade SIL, in 83% of women who had
high-grade SIL, and in 90% of women who had cervical can-
cer. Low-risk HPV infection was detected in 22%, 8%, and 3%
of these women, respectively. No evidence of HPV infection
was found in 22%, 9%, and 7% of these women, respectively
(1–7). We then calculated relative progression rates for transi-
tion from high-risk, low-risk, or no HPV infection to low-
grade SIL; from low-grade to high-grade SIL; and from high-
grade SIL to cervical cancer (Appendix). 
Cancer Surveillance, Treatment, and Progression
We estimated that 71% of the adult female population
received biennial Pap testing. Pap test sensitivity and specific-
ity results were based on a meta-analysis conducted by the
Duke Evidence-Based Practice Center (17,23). Diagnosis of
asymptomatic cervical lesions depended on a woman’s likeli-
hood of having a Pap test and on the sensitivity and specificity
of this test. 
Assessment of treatment effectiveness for cervical lesions
was based on a review of 13 studies that detailed treatment
effectiveness by lesion stage (Appendix). Initial treatment
effectiveness was estimated at 97% and 94% for low-grade
and high-grade SIL, respectively. Unsuccessful initial treat-
ment of cervical lesions was followed with a repeat treatment
(cryotherapy or LEEP) (77%), cone biopsy (18%), or hysterec-
tomy (5%) (24), increasing treatment success. We based can-
cer progression rates, annual patient survival rates, and
probability of symptoms by cancer stage on an analysis by
Myers et al. (Appendix) (17). Myers et al. validated their data
by comparing predicted distribution of cancer by stage for an
unscreened population with data from studies of women who
had had no prior screening.
Benign Hysterectomy
We considered women who did not have cervical cancer
but who had hysterectomies to be fully protected from cervical
cancer. We tested this assumption in sensitivity analyses. Age-
specific hysterectomy rates were based on data from the Hos-
pital Discharge Survey of the National Center for Health Sta-
tistics (Appendix).
HPV Vaccine Characteristics
In our model the HPV vaccine was administered by using a
series of three injections in a school-based immunization pro-
gram. Because vaccine longevity is uncertain, we assumed that
successful vaccination conferred immunity for 10 years but
that repeated booster shots every 10 years were required to
maintain the vaccine’s efficacy. We evaluated the need for
more frequent booster shots or a vaccine that conferred life-
time immunity in sensitivity analysis. For our base-case analy-
sis, vaccine efficacy against high-risk HPV types was
estimated at 75%. We tested the complete range of vaccine
effectiveness (from 0% to 100%) because of the absence of
efficacy data from Phase III clinical trials and because future
marketed vaccines may target only a subset of the high-risk
HPV types.
Quality of Life
HPV infection and cervical cancer can markedly affect
quality of life and therefore can affect a woman’s quality-
adjusted life expectancy. Accordingly, we incorporated adjust-
ments for quality of life associated with current health, HPV,
SIL, and with cervical cancer and its treatment. 
Utilities for health states were based on a report by the
Institute of Medicine on Vaccines for the 21st Century, which
used committee-consensus Health Utility Indices levels for
relevant health states (Appendix). Undiagnosed HPV and cer-
vical lesions were considered to be asymptomatic and to have
no utility decrement. Diagnosed and treated low- and high-
grade SIL were assigned lower utilities (0.97) for a 1-year
duration. Treatment for locally invasive cancer was assigned a
low utility (0.79–0.80) during 4 months of initial treatment,
with a moderate utility (0.90–0.97) during a 2- or 3-year fol-
low-up. For more advanced cancer, a woman’s utility was
decreased to 0.62 during both treatment and follow-up to
reflect the severity of her disease and its effects on quality of
life. We based current health utilities on the gender- and age-
specific data from the Beaver Dam study (25).
Costs
We converted all costs to 2001 U.S. dollars by using the
gross-domestic-product deflator. Pap-testing costs were $81
per test, including a 10% rescreen rate. We estimated the cost
of the vaccine materials, personnel, and administration at
$300, based on school-based HBV vaccination programs
(Appendix). We assumed a three-injection protocol with a
booster shot ($100) required every 10 years.
Treatment costs of low- and high-grade SIL were based on
Medicare average reimbursements and resource-based cost
estimates. We estimated the cost of treatment of low-grade SIL
from the cost of an initial colposcopy and biopsy, cryotherapy
(in 10% of patients), a 6-week reexamination, and Pap tests at
3, 6, 12, and 18 months after treatment. The cost of treatment
of high-grade SIL was based on cost of initial colposcopy and
biopsy, LEEP, and subsequent reexamination and Pap tests.
Cost of cancer treatment varied, depending on the stage at
which cancer was diagnosed. Costs were based on Medicare
average reimbursement rates (26) and cross-checked with a
1999 HMO case-control full-cost analysis (27) (Appendix). 
Sensitivity Analysis
We performed one-way and multi-way sensitivity analyses
to account for important model uncertainties. For clinical vari-RESEARCH
40 Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003
ables, our ranges for sensitivity analyses represent our judg-
ment of the variation likely to be encountered in clinical
practice, based on the literature and on discussion with
experts. The ranges for costs represent variation by 25% above
and below the base-case estimate. To determine ranges for util-
ities, we used clinical judgment. 
Results
Model Validation
We evaluated outcomes in the current practice arm of the
model to ensure that they reflected the frequency of events
from the Surveillance, Epidemiology and End Results (SEER)
registry. Our model’s annual rates of cervical-cancer cases and
cervical-cancer-related deaths match 2001 SEER estimates, as
well as those calculated by the Myers model (17) (data avail-
able from the authors).
Base-Case Analysis
A prophylactic vaccine against high-risk HPV types is
more expensive than current practice but results in greater
quality-adjusted life expectancy (Table 1). HPV vaccination of
12-year-old girls improves their life expectancy by 2.8 days or
4.0 quality-adjusted life days at a cost of $246 relative to cur-
rent practice (ICE of $22,755/QALY). 
Vaccinating the present U.S. cohort of 12-year-old girls
(population approximately 1,988,600) averts >224,255 cases
of HPV, 112,710 cases of SIL, 3,317 cases of cervical cancer,
and 1,340 cervical-cancer deaths over the cohort’s lifetime.
Prevention of one case of cervical cancer would require vacci-
nation of 600 girls (Table 2). 
Sensitivity Analyses
Figure 2 shows the ICE ratios of one-way sensitivity
analyses of the vaccination strategy compared to current prac-
tice. We explored those variables with the greatest effect on
the ICE ratio by running more extensive sensitivity analyses.
Given the uncertainty surrounding the vaccine efficacy, pric-
ing, and mechanism, we performed extensive sensitivity anal-
yses using vaccine-related variables.
In our base-case analysis, we estimated that an HPV vac-
cine would provide immunity against high-risk HPV types in
75% of the girls vaccinated. At early stages of vaccine devel-
opment or given a vaccine that targets only selected high-risk
HPV types, the efficacy may prove to be lower. Sensitivity
analyses on the vaccine efficacy and cost showed that even if
the efficacy was reduced to 40% or the vaccine cost was
increased to $600, vaccination costs <$50,000/QALY, relative
to current practice (Figures 3 and 4).
We assumed that vaccination required a one-shot booster
every 10 years. We also considered that vaccination could pro-
vide lifetime immunity, in which case the ICE improved to
$12,682/QALY. Vaccinating the present U.S. cohort of 12-
year-old girls with such a lifetime vaccine would avert
>272,740 cases of HPV, 174,208 cases of SIL, 7,992 cases of
cervical cancer, and 3,093 cervical-cancer deaths over the
cohort’s lifetime. Prevention of one case of cervical cancer
would require vaccination of 250 girls. Even if a booster shot
is required every 3 years, the vaccine compared to current
practice remained fairly cost effective ($45,599/QALY) (Fig-
ures 3 and 4). Our model assumes that a vaccination program
would target 12-year-old girls for vaccination. Waiting until
girls are 15 years old to provide vaccination results in a
slightly lower life expectancy (reducing quality-adjusted life
expectancy by 0.2 days) though at a reduced cost ($20). Vacci-
nation of 12-year-old girls as compared to 15-year-old girls
costs $40,440 per additional quality-adjusted life year gained.
Although the estimates used in our analysis reflect current
Pap-test characteristics and compliance, if every woman
obtained a Pap test every 2 years (base-case estimate is 71%
compliance every 2 years), the ICE of vaccination increases to
$33,218/QALY. Our base-case analysis assumes that vacci-
nated women would continue to receive Pap tests at the same
Table 1. Health and economic outcomes of HPV vaccinationa
Outcome No vaccination HPV vaccination
Cost, $ 39,682 39,928
Incremental cost, $ 246
Life expectancy, yrs 28.785 28.793
Incremental life expectancy, days 2.8
Quality-adjusted life expectancy, yrs 27.720 27.731
Incremental quality-adjusted life 
expectancy, days
4.0
Incremental cost effectiveness
$/life year 32,066
$/quality-adjusted life year 22,755
aHPV, Human papillomavirus.
Table 2. Intermediate health outcomes of HPV vaccinationa,b
Outcome HPV vaccination No vaccination Lifetime cases averted No. needed to vaccinate to prevent one case
HPV 1,460,699 1,684,954 224,255 9
SIL 417,549 530,259 112,710 18
Cervical cancer 13,374 16,690 3,316 600
Cervical-cancer deaths 5,121 6,461 1,340 1,484
aAssumes program that successfully administers a vaccine against high-risk HPV to the current U.S. cohort of 12-year-old girls.
bHPV, Human papillomavirus; SIL, squamous intraepithelial lesions.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 41
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frequency as unvaccinated women. HPV vaccination and the
resulting reduction in cervical-cancer risk, however, might
decrease frequency of Pap testing. Figure 5 shows how the
costs and quality-adjusted life expectancy are influenced by
the frequency of Pap tests in the vaccinated cohort. A strategy
in which vaccinated women have Pap testing every 4 years
increases life expectancy while reducing costs compared to
current practice. While providing more frequent Pap tests to
vaccinated women does increase a woman’s quality-adjusted
life expectancy, it also increases costs. The cost-effectiveness
ratios of more frequent testing are shown in Figure 5.
Our results were sensitive to several of our base-case
assumptions (Figure 2). Vaccination saved 11.4 quality-
adjusted life days and cost $290 over current practice when
costs and benefits were not discounted (ICE of $9,286/QALY).
At a discount rate of 5%, vaccination cost $37,752/QALY.
Some women may be quite alarmed by being diagnosed with
high-grade SIL; decreasing the utility of high-grade SIL to 0.8
lowers the cost-effectiveness ratio to $16,927/QALY. Varying
the underlying incidence of HPV from 0.5 to 2 times our base-
case values resulted in cost-effectiveness ratios ranging from
$43,088 to $12,664 per QALY, respectively. Sensitivity analy-
ses with other variables did not change our results substan-
tially (Figure 2).
Discussion
We evaluated the usefulness of a potential vaccine against
high-risk HPV types administered to adolescent girls and
found it to be cost effective as compared to current practice
($22,755/QALY). Although the increase in quality-adjusted
life expectancy from a vaccination program is modest for the
individual, the increase aggregates to substantial numbers of
HPV infections, cases of cervical cancer, and prevented can-
cer-related deaths (Table 2). Furthermore, the life-expectancy
gains are similar to those realized by current vaccination pro-
grams. Vaccination against high-risk HPV saved 2.8 life days
and 4.0 quality-adjusted life days per person. In comparison,
vaccinations against measles, mumps, rubella, and pertussis
each save 2.7, 3.0, 0.3, and 3.3 life days, respectively (28,29).
Sensitivity analyses found that the HPV vaccine would be cost
effective, even assuming vaccine efficacy as low as 40% or
that booster shots would be required every 3 years.
The only previous analysis of the cost effectiveness of a
vaccine against HPV was published by the Institute of Medi-
cine (IOM) (30). That analysis also showed an HPV vaccine to
be cost effective. Our analysis differs from the IOM’s, how-
ever, in that we modeled a vaccine specific to high-risk types
of HPV because such vaccines are under development and in
clinical trials. In addition, our progression and recurrence rates
are HPV-type specific.
Figure 2. Sensitivity analysis. Tornado diagram representing the incre-
mental cost-effectiveness ratios of one-way sensitivity analysis on the
vaccination strategy compared to current practice. The vertical line rep-
resents the incremental cost-effectiveness ratio under base-case condi-
tions.
Figure 3. Sensitivity analysis: Vaccine efficacy. Effect of a change in
Human papillomavirus (HPV) vaccine efficacy on the cost effectiveness
of vaccination compared with current practice under varying assump-
tions of vaccine immunity. The triangles represent a vaccine which pro-
vides lifetime immunity to high-risk types of HPV. The circles represent
a vaccine which requires booster shots every 10 years to remain effec-
tive (base-case assumption). The hatches represent a vaccine that
requires booster shots every 5 years to remain effective. The dashed
lines indicate the $50,000and $100,000 per quality-adjusted life year
cost-effectiveness thresholds. The base-case value of 75% efficacy is
indicated by the arrow.RESEARCH
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Our analysis does have limitations. We analyzed the bene-
fits and costs of vaccinating only adolescent girls against HPV.
Because HPV is sexually transmitted, reducing the prevalence
of HPV in the population will also affect the prevalence of
HPV in women’s sexual partners. Although HPV is most com-
monly associated with cervical cancer, it may also play a role
in cancers of the anus, vulva, vagina, and penis. The benefits
of HPV vaccination associated with reductions in these types
of cancers are not included in our analysis. Including them
should make HPV vaccination even more favorable. The deci-
sion whether to vaccinate adolescent boys as well is more
complex; therefore, in future work we plan to extend our anal-
ysis to incorporate such costs and benefits. In addition, the
costs and benefits used in this analysis are tailored to the popu-
lation and health-care environment of the United States. As
Figure 5 demonstrates, the availability of HPV vaccines may
justify less frequent Pap tests. This effect may be particularly
relevant in developing countries that must decide how best to
allocate their limited health-care resources. 
We make several assumptions about the target vaccination
population and program implementation that need discussion
in terms of their political and social feasibility. First, we pro-
pose a school-based vaccination program rather than a clinic-
based one. School-based immunization programs address sev-
eral challenges encountered when vaccinating adolescents.
First, school-based programs provide an infrastructure in
which to vaccinate adolescents. Adolescent health-care visits
are often not routine, and given scheduled visits, adolescents
are often noncompliant with appointments. In addition, we
believe that fitting the three-dose HPV vaccination regimen
into the academic year will increase compliance while contain-
ing costs. Several school-based programs have documented
completion rates of >90%. In contrast, lower rates of comple-
tion (11% to 87%) have been found in more traditional health-
care settings (31–34). Second, we propose providing universal
vaccination rather than targeting specific high-risk groups.
Certain groups of women are at higher risk for HPV infection,
and the cost effectiveness of vaccinating such target groups
may be more favorable than a universal vaccination program.
Experience with Hepatitis B vaccination in adolescents, how-
ever, has demonstrated how such groups may be those that are
hardest to reach (13,14,35), and that many risk factors for
infection (such as number of partners) may not be readily iden-
tifiable (13,14). Finally, we propose vaccinating girls at an
early adolescent age (12 years). Although the lifetime cost of
vaccinating 12-year-old girls is slightly greater than that of
vaccinating 15-year-old girls, earlier vaccination costs
<$50,000 per QALY when compared to costs of vaccinating
older adolescents. A significant proportion of adolescents are
sexually active by 15 years of age; therefore, vaccination at 12
years of age aims to include as many girls as possible before
sexual activity begins and HPV infection risk increases. In
addition, studies using Hepatitis B vaccines as a proxy have
found better immune responses in younger persons and have
shown that younger children require lower doses (36,37).
Finally, we believe a 3-dose school-based vaccination program
aimed at 12-year olds will result in greater compliance because
adolescents of this age have more consistent school attendance
(13,38–40). Before a HPV vaccination program is successfully
implemented, social and political issues will need to be
addressed and agreed upon by stakeholder groups, including
pediatricians, public health officers, parents, adolescents,
school administrators, and community leaders. 
Several institutions, including Merck Research Laborato-
ries, MedImmune Inc., GlaxoSmithKline, and the National
Cancer Institute (NCI), are developing and testing prophylac-
tic HPV vaccines. Researchers at NCI and Johns Hopkins have
developed a virus-like particle vaccine with promising initial
results (9,10). If the results of the recently completed Phase II
Figure 4. Sensitivity analysis: Vaccine cost. Effect of a change in Human
papillomavirus (HPV) vaccine cost on the cost effectiveness of vaccina-
tion compared with current practice under varying assumptions of vac-
cine immunity. The triangles represent a vaccine that provides lifetime
immunity to high-risk types of HPV. The circles represent a vaccine that
requires booster shots every 10 years to remain effective (base-case
assumption). The hatches represent a vaccine that requires booster
shots every 5 years to remain effective. The dashed lines indicate the
$50,000 and $100,000 per quality-adjusted life year cost-effectiveness
thresholds. The base-case value of $300 is indicated by the arrow. 
Figure 5. Sensitivity analysis: Frequency of Pap tests in vaccinated
women. Effect of changing the frequency with which vaccinated women
receive a Pap test. The diamonds represent Pap testing vaccinated
women annually, every 2 years (base case), every 3 years, every 4
years, and every 5 years. The x-axis represents the lifetime expected
cost of the vaccination strategy; the y-axis is the quality-adjusted life
expectancy in years. The incremental cost effectiveness of increasing
the frequency of Pap testing for vaccinated women is indicated numeri-
cally above the cost-effectiveness frontier.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 43
RESEARCH
study in the United States and Costa Rica confirm the Phase I
results, a Phase III trial in Costa Rica involving 10,000 women
will begin. Nonetheless, a vaccine probably will not be
approved for widespread use for 3–5 years. Meanwhile, the
need for continued cervical-cancer screening and treatment
programs remains high. 
Our study suggests that vaccination of girls with a HPV
vaccine is cost effective when compared to many other gener-
ally acceptable health interventions. Although HPV vaccines
are still under development, our assessment of the cost effec-
tiveness, however, is robust across a wide range of vaccine
mechanisms and efficacies. Although several hurdles to an
HPV vaccine must be overcome before it is widely dissemi-
nated, our analysis suggests that a vaccine against high-risk
HPV would have substantial public health benefit and empha-
sizes the importance of ongoing vaccine research and develop-
ment. 
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Appendix Table. Input variables and sourcesa
Input variable Base-case estimate Range Source
Demographic variables
Population starting age, y 12 0–25 Assumed
Vaccine variables
Vaccine effectiveness, % 75 0–100 Estimate
Vaccine compliance, % 70 30–100 (1,2)
Booster shot frequency, y 10 3–lifetime Assumed
Treatment variables
Initial treatment efficacy, given high-grade SIL, % 95 88–97 (3–6)
Treatment efficacy (including retreat), given high-grade SIL, % 99.5 99–100 (3–7)
Probability HPV infection persists, given effective treatment of high-grade SIL 10 0–25 Assumed
Initial treatment efficacy, given low-grade SIL, % 98 93–100 (8–10)
Treatment efficacy (including retreatment), given low-grade SIL, % 99.5 99–100 (7–10)
Probability HPV infection persists, given effective treatment of low-grade SIL 10 0–25 Assumed
Surveillance variables
Pap test sensitivity for SIL (both low- and high-grade) 51 40–80 (11,12) 
Pap test specificity for SIL (both low- and high-grade) 97 95–98 (11,12)
Compliance with Pap testing, % 71 60–80 (13,14)
Pap testing frequency in unvaccinated population, months 24 12–60 (13,14)
Pap testing frequency in vaccinated population, months 24 12–60 (13,14)
HPV variables
Prevalence of HPV in initial cohort population, % 0 0–25 (12,15)
Annual incidence of HPV infection, given woman aged (yrs): 0.5–2x (12)
0–15 0
15–16 0.1
17 0.12
18 0.15
19 0.17
20 0.15
21 0.12
22–23 0.10
24–29 0.05
30–49 0.01Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 45
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Appendix Table continued. Input variables and sourcesa
Input variable Base-case estimate Range Source
50+  0.005
Proportion of high-risk HPV infections, %a 59 52–72 (16–19)
Annual probability (%) of HPV infection resolving, woman aged (yrs): (12,18,20,21)
0–24 45.7 40–55
25–29 32.9 30–37
30+  6.8 4–10
SIL variables
Annual probability of SIL, given no HPV infection, % 0.025 0.02–0.03 (22–26)
Annual probability of SIL, given low-risk HPV infection, % 3.6 3–5 (12,14,22–27)
Annual probability of SIL, given high-risk HPV infections, % 6.5 5–8 (12,14,22–27)
Low-grade SIL, given no HPV infection, % 100 90–100 Assumed
Low-grade SIL, given HPV infection, % 90 80–100 (12)
Annual probability (%) of low-grade SIL regressing, given woman aged (yrs): (27–36)
0–34 14.2 12–16
35–44 5.8 4–8
45+ 2.7 2–8
Probability of low-grade SIL regressing to previous state of HPV infection, given regression occurs, % 10 0–20 (12)
Annual probability (%) of high-grade SIL regressing, given woman aged (yrs):  (27,28,30,31)
0–44 5.8 3–7
45+ 3.7 3–7
Probability of high-grade SIL regressing to well state, given regression, % 45 40–50 (12)
Probability of high-grade SIL regressing to previous state of HPV infection, given regression, % 5 0–10 Assumed
Probability of high-grade SIL regressing to low-grade SIL given regression, % 50 40–60 (12)
Annual probability (%) of developing high-grade SIL from low-grade SIL with no HPV infection, women aged (yrs): (12,14,22–27) 
0–34 0.5 0.3–0.7
35–44 3.1 2–5
45+ 4.5 3–6
Annual probability (%) of developing high-grade SIL from low-grade SIL when low-risk HPV infection is present, 
women aged (yrs):
(12,14,22–27) 
0–34 0.4 0.2–0.6
35–44 2.7 2–4
45+ 3.8 3–5
Annual probability (%) of developing high-grade SIL from low-grade SIL when high-risk HPV infection is present, 
women aged (yrs):
(12,14,22–27)
0–34 2.0 1–3
35–44 15.6 7–20
45+ 31.3 15–35
Annual probability of developing cervical cancer, given high-grade SIL and no HPV infection, % 2.6 2–4 (12,14,22–27) 
Annual probability of developing cervical cancer, given high-grade SIL developed through low-risk HPV infection, % 1.0 0.7–1.5 (12,14,22–27)
Annual probability of developing cervical cancer, given high-grade SIL developed through high-risk HPV infection, % 3.8 3–6 (12,14,22–27)
Cervical cancer variables
Annual probability of progressing from undiagnosed Stage I cervical cancer to Stage II cervical cancer, % 43.7 40–45 (12)
Annual probability of progressing from undiagnosed Stage II cervical cancer to Stage III cervical cancer, % 53.5 50–55
Annual probability of progressing from undiagnosed Stage III cervical cancer to Stage IV cervical cancer, % 68.3 65–70
Annual probability of symptoms with undiagnosed Stage I cervical cancer, % 15 12–18
Annual probability of symptoms with undiagnosed Stage II cervical cancer, % 22.5 20–25RESEARCH
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Appendix Table continued. Input variables and sourcesa
Input variable Base-case estimate Range Source
Annual probability of symptoms with undiagnosed Stage III cervical cancer, % 60 67–73
Annual probability of symptoms with undiagnosed Stage IV cervical cancer, % 90 87–93
Annual probability of survival after diagnosis, by stage: (12)
Stage I
Year 1 0.9688 0.95–0.99
Year 2 0.9525 0.93–0.97
Year 3 0.9544 0.93–0.97
Year 4 0.9760 0.95–0.99
Year 5 0.9761 0.95–0.99
Stage II
Year 1 0.9066 0.88–0.92
Year 2 0.8760 0.85–0.89
Year 3 0.9225 0.90–0.94
Year 4 0.9332 0.91–0.95
Year 5 0.9604 0.94–0.98
Stage III
Year 1 0.7064 0.68–0.72
Year 2 0.7378 0.71–0.75
Year 3 0.8610 0.84–0.88
Year 4 0.9231 0.90–0.94
Year 5 0.9142 0.89–0.93
Stage IV
Year 1 0.3986 0.37–0.41
Year 2 0.4982 0.47–0.51
Year 3 0.7638 0.74–0.78
Year 4 0.8652 0.84–0.88
Year 5 0.8592 0.83–0.87
Time to remission, yrs 5
Five-year survival after diagnosis, by stage, % (12)
Stage I 83.9
Stage II 65.66
Stage III 37.87
Stage IV 11.27
Costs, $
Vaccine 300 100–500 (37–40)
Booster shot 100 30–130 Assumed
Cost of treatment for cervical cancer, Stage I 14,979 11,234–18,724 (41,42)
Cost of treatment for cervical cancer, Stage II 21,811 16,358–27,264 (41,42)
Cost of treatment for cervical cancer, Stage III 21,811 16,358–27,264 (41,42)
Cost of treatment for cervical cancer, Stage IV 24,004 18,003–30,005 (41,42)
Cost of Pap test (w/10% retest) 81 61–101 (42)
Cost of treatment for high-grade SIL 1,218 914–1523 (42–45)
Cost of treatment for low-grade SIL 630 473–788 (42–45)
Cost of treatment for a false-positive SIL 230 172–288 (43,44,46)
Cost of hysterectomy 7,883 5912–9854 (11,45)Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 47
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Appendix Table continued. Input variables and sourcesa
Input variable Base-case estimate Range Source
Annual probability of hysterectomy by age (yrs), % 0.25–2x (47)
15–24 0.04
25–29 0.35
30–34 0.60
35–39 0.99
40–44 1.29
45–54 0.99
>55 0.33
Utilities (48)
Low-grade SIL 0.97 0.8–1
High-grade SIL 0.97 0.5–1
Low-risk HPV infection 1.00 0.9–1
High-risk HPV infection 1.00 0.8–1
Cervical cancer, treatment phase
Stage I 0.79 0.25–1
Stages II–IV 0.62 0.25–1
Cervical cancer, follow-up
Stage I 0.90 0.25–1
Stages II–IV 0.62 0.25–1
Well 1.00 Age-specific utili-
ties based on (49)
Other Variables
Markov model cycle length, months 1 Assumed
Discount rate, % 3 0–5 (50)
aHPV, Human papillomavirus; SIL,  squamous intraepithelial lesion. High risk HPV is defined as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68; low-risk HPV is defined as all 
other types. All probabilities are annual unless otherwise noted. All costs are in 2001 U.S. dollars.
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